Abeona Therapeutics Company Profile (NASDAQ:ABEO)

About Abeona Therapeutics

Abeona Therapeutics logoAbeona Therapeutics, Inc. (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company's lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. The Company is also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD), and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a clustered, regularly interspaced short palindromic repeats (CRISPR)/Cas9-based gene editing approach to gene therapy program for rare blood diseases. It is developing rare plasma protein therapies, including PTB-101 SDF Alpha (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease. Its product pipeline also consists of MuGard and ProdiGard.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ABEO
  • CUSIP:
Key Metrics:
  • Previous Close: $5.10
  • 50 Day Moving Average: $5.23
  • 200 Day Moving Average: $5.57
  • 52-Week Range: $2.05 - $9.44
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.23
  • P/E Growth: 0.00
  • Market Cap: $197.80M
  • Outstanding Shares: 39,959,000
  • Beta: 1.79
Profitability:
  • Net Margins: -2,029.60%
  • Return on Equity: -26.65%
  • Return on Assets: -22.54%
Debt:
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 4.91%
  • Quick Ratio: 4.91%
Additional Links:
Companies Related to Abeona Therapeutics:

Analyst Ratings

Consensus Ratings for Abeona Therapeutics (NASDAQ:ABEO) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $16.83 (230.07% upside)

Analysts' Ratings History for Abeona Therapeutics (NASDAQ:ABEO)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017FBR & CoReiterated RatingOutperform$15.00View Rating Details
2/17/2017Maxim GroupSet Price TargetBuy$14.00View Rating Details
2/17/2017Cantor FitzgeraldReiterated RatingOverweight -> Positive$21.00View Rating Details
2/17/2017Jefferies Group LLCReiterated RatingHold$11.00View Rating Details
2/6/2017HC WainwrightSet Price TargetBuy$20.00View Rating Details
2/7/2017Rodman & RenshawReiterated RatingBuy$17.00 -> $20.00View Rating Details
7/20/2015MLV & Co.Initiated CoverageBuy$15.00View Rating Details
6/11/2015Roth CapitalInitiated CoverageBuy$16.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017        
11/10/2016Q316($0.19)($0.08)ViewN/AView Earnings Details
8/16/2016Q2($0.14)($0.20)ViewN/AView Earnings Details
5/16/2016Q1($0.13)($0.17)ViewN/AView Earnings Details
3/8/2016Q415($0.07)ViewN/AView Earnings Details
8/20/2015Q215($0.10)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
Current Year EPS Consensus Estimate: $-0.59 EPS
Next Year EPS Consensus Estimate: $-0.62 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.17)($0.17)($0.17)
Q4 20161($0.10)($0.10)($0.10)
Q1 20171($0.11)($0.11)($0.11)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Abeona Therapeutics (NASDAQ:ABEO)
Insider Ownership Percentage: 13.00%
Institutional Ownership Percentage: 17.79%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/20/2016Todd WiderDirectorBuy5,000$5.48$27,400.00View SEC Filing  
7/31/2015Mark J AhnDirectorBuy18,182$5.50$100,001.00View SEC Filing  
1/26/2015Mark J AhnDirectorBuy25,000$4.00$100,000.00View SEC Filing  
12/24/2014Steven H RouhandehDirectorBuy250,000$4.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
DateHeadline
News IconShare Tracker: Abeona Therapeutics Inc. (NASDAQ:ABEO) - BVN (NASDAQ:ABEO)
bvnewsjournal.com - February 23 at 3:17 PM
finance.yahoo.com logoAbeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit - Yahoo Finance (NASDAQ:ABEO)
finance.yahoo.com - February 23 at 3:17 PM
News IconInvestor Monitor: Narrowing in on Abeona Therapeutics Inc. (NASDAQ:ABEO) - Midway Monitor (NASDAQ:ABEO)
midwaymonitor.com - February 22 at 3:15 PM
News IconErratic Volume Stretches This Stock Mid-Session: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Aiken Advocate (NASDAQ:ABEO)
aikenadvocate.com - February 21 at 3:32 PM
finance.yahoo.com logoAbeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR Congress (NASDAQ:ABEO)
finance.yahoo.com - February 21 at 3:32 PM
News IconAnalysts Positive on Abeona Therapeutics' (ABEO) Low-Dose Clinical Trial Data - Economic Calendar (NASDAQ:ABEO)
www.economiccalendar.com - February 21 at 5:25 AM
marketexclusive.com logoABEONA THERAPEUTICS INC. (NASDAQ:ABEO) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:ABEO)
marketexclusive.com - February 20 at 5:15 AM
News IconReviewing the Levels for Abeona Therapeutics Inc. (NASDAQ:ABEO) - BVN (NASDAQ:ABEO)
bvnewsjournal.com - February 18 at 3:15 PM
marketexclusive.com logoAnalyst Activity – Jefferies Group LLC Reiterates Hold on Abeona Therapeutics (NASDAQ:ABEO) - Market Exclusive (NASDAQ:ABEO)
marketexclusive.com - February 18 at 3:15 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Provides Update from ABO-102 ... - StreetInsider.com (NASDAQ:ABEO)
www.streetinsider.com - February 18 at 3:15 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial (NASDAQ:ABEO)
www.streetinsider.com - February 18 at 9:24 AM
finance.yahoo.com logo7:46 am Abeona Therapeutics presents updated data from its trial for Sanfilippo syndrome Type A at the 13th Annual WORLDSymposium (NASDAQ:ABEO)
finance.yahoo.com - February 17 at 6:49 PM
finance.yahoo.com logoAbeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium™ 2017 (NASDAQ:ABEO)
finance.yahoo.com - February 17 at 6:49 PM
biz.yahoo.com logoABEONA THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ABEO)
biz.yahoo.com - February 17 at 6:49 PM
News IconStock Spotlight: Zooming in on Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) - Searcy News (NASDAQ:ABEO)
searcysentinel.com - February 16 at 3:17 PM
News IconMarket Stir – Advanced Volatility Spotted on Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) - Aiken Advocate (NASDAQ:ABEO)
aikenadvocate.com - February 16 at 3:17 PM
finance.yahoo.com logo3 Companies Looking to Capitalize on Orphan Designation with Multiple Catalyst (NASDAQ:ABEO)
finance.yahoo.com - February 16 at 3:17 PM
finance.yahoo.com logoAbeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8% (NASDAQ:ABEO)
finance.yahoo.com - February 16 at 5:59 AM
News IconSteady as She Goes, Shares Hover Above Trend Lines Abeona Therapeutics Inc. (NASDAQ:ABEO) - Winfield Review (NASDAQ:ABEO)
winfieldreview.com - February 15 at 1:26 AM
News IconAverage Directional Index Review for Abeona Therapeutics Inc. (ABEO) - BVN (NASDAQ:ABEO)
bvnewsjournal.com - February 15 at 1:26 AM
News IconTrading Notes – Active Stock Recap on Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) - Winfield Review (NASDAQ:ABEO)
winfieldreview.com - February 14 at 8:24 PM
News IconErratic Volume Takes A Hold of This Stock: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Aiken Advocate (NASDAQ:ABEO)
aikenadvocate.com - February 14 at 3:21 PM
seekingalpha.com logoAbeona: Preparing For Liftoff - The Next AveXis? - Seeking Alpha (NASDAQ:ABEO)
seekingalpha.com - February 14 at 3:21 PM
News IconEarnings Take Center Stage; Analysts Weighing in on Abeona Therapeutics Inc (NASDAQ:ABEO) - Aiken Advocate (NASDAQ:ABEO)
aikenadvocate.com - February 13 at 3:20 PM
News IconInvestor Update: Looking at Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) - Benton Bulletin (NASDAQ:ABEO)
bentonbulletin.com - February 11 at 1:20 AM
prnewswire.com logoABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving ... - PR Newswire (press release) (NASDAQ:ABEO)
www.prnewswire.com - February 11 at 1:20 AM
us.rd.yahoo.com logoABEO UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Abeona Therapeutics Inc. and a Lead Plaintiff Deadline of February 14, 2017 (NASDAQ:ABEO)
us.rd.yahoo.com - February 10 at 8:19 PM
einnews.com logoAbeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017 - EIN News (press release) (NASDAQ:ABEO)
www.einnews.com - February 9 at 1:41 AM
News IconLosing Traction in Session: Abeona Therapeutics Inc. (NASDAQ:ABEO) - Aiken Advocate (NASDAQ:ABEO)
aikenadvocate.com - February 8 at 8:35 PM
globenewswire.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona ... - GlobeNewswire (press release) (NASDAQ:ABEO)
globenewswire.com - February 8 at 3:20 PM
prnewswire.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Abeona Therapeutics ... - PR Newswire (press release) (NASDAQ:ABEO)
www.prnewswire.com - February 8 at 3:20 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces Presentations and Posters at WORLDSymposium - StreetInsider.com (NASDAQ:ABEO)
www.streetinsider.com - February 8 at 3:20 PM
streetinsider.com logoAbeona Therapeutics (ABEO) Announces Presentations and Posters at WORLDSymposium (NASDAQ:ABEO)
www.streetinsider.com - February 7 at 8:20 PM
businesswire.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Abeona Therapeutics Inc. of a Class Action ... - Business Wire (press release) (NASDAQ:ABEO)
www.businesswire.com - February 7 at 3:18 PM
marketexclusive.com logoAnalyst Activity – Rodman & Renshaw Reiterates Buy on Abeona Therapeutics (NASDAQ:ABEO) - Market Exclusive (NASDAQ:ABEO)
marketexclusive.com - February 7 at 3:18 PM
finance.yahoo.com logoAbeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium™ 2017 (NASDAQ:ABEO)
finance.yahoo.com - February 7 at 3:17 PM
finance.yahoo.com logoAbeona Therapeutics Announces Presentations and Posters at the 13th Annual WORLDSymposium(TM) 2017 (NASDAQ:ABEO)
finance.yahoo.com - February 7 at 3:17 PM
finance.yahoo.com logoEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Abeona Therapeutics Inc. - ABEO (NASDAQ:ABEO)
finance.yahoo.com - February 7 at 3:17 PM
finance.yahoo.com logoFebruary 14th Deadline in Lawsuit for Investors in Abeona Therapeutics Inc (NASDAQ:ABEO) shares announced by Shareholders Foundation (NASDAQ:ABEO)
finance.yahoo.com - February 6 at 3:19 PM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Abeona Therapeutics Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 14, 2017 (NASDAQ:ABEO)
finance.yahoo.com - February 6 at 3:19 PM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ABEO)
finance.yahoo.com - February 6 at 3:19 PM
wsj.com logo[$$] Clinical Development News, Jan. 30-Feb. 3 (NASDAQ:ABEO)
www.wsj.com - February 6 at 3:19 PM
us.rd.yahoo.com logoDEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Abeona Therapeutics Inc. (ABEO) and Lead Plaintiff Deadline - February 14, 2017 (NASDAQ:ABEO)
us.rd.yahoo.com - February 3 at 8:15 PM
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona ... - Yahoo Finance (NASDAQ:ABEO)
finance.yahoo.com - February 3 at 3:15 PM
News IconDeadline Upcoming in Lawsuit for Investors in Abeona Therapeutics Inc (NASDAQ:ABEO) (NASDAQ:ABEO)
www.digitaljournal.com - February 2 at 8:17 PM
globenewswire.com logoAbeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo ... - GlobeNewswire (press release) (NASDAQ:ABEO)
globenewswire.com - February 1 at 3:21 PM
finance.yahoo.com logoAbeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A (NASDAQ:ABEO)
finance.yahoo.com - February 1 at 3:21 PM
finance.yahoo.com logoLD Micro Index Reconstitution as of February 1, 2017 (NASDAQ:ABEO)
finance.yahoo.com - February 1 at 3:21 PM
finance.yahoo.com logoABEO SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving … (NASDAQ:ABEO)
finance.yahoo.com - January 31 at 3:17 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm (NASDAQ:ABEO)
finance.yahoo.com - January 31 at 3:17 PM

Social

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2017?

6 brokerages have issued 12-month price targets for Abeona Therapeutics' stock. Their forecasts range from $11.00 to $21.00. On average, they anticipate Abeona Therapeutics' stock price to reach $16.83 in the next year.

When will Abeona Therapeutics announce their earnings?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 6th 2017.

What are analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:

  • FBR & Co analysts commented, "On February 17, Abeona provided an update on its ongoing Phase I/II gene therapy trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA), which was presented at the 13th WORLDSymposium, an annual research meeting and forum of the latest advances in lysosomes and lysosomal storage diseases. We view the six-month results as positive as low-dose ABO-102 therapy is achieving several important objectives: continued reduction of GAG in the cerebrospinal fluid (CSF), further reductions in liver and spleen volume, all of which are symptoms that arise in MPS IIIA, and positive signals in cognitive stabilization. Albeit data was only from two subjects, the 63% reduction in GAGs in the CSF was particularly notable as this is a key measure of reduction in storage pathology in the central nervous system (CNS). We look for news flow from the ABO-102 high-dose cohort, as well as Abeona's three other ongoing rare disease clinical programs in the next three to six months to be positive catalysts for ABEO stock. We reiterate our Outperform rating." (2/17/2017)
  • Maxim Group analysts commented, "At WORLDSymposium (Feb 13-17) Abeona presented updated data from the ongoing phase I/II study of ABO-102 in Sanfilippo Syndrome. The first two patients with 180 days of followup continued to experience decreased heparin sulfates (HS) in the central nervous system, reduced total GAGs (sugars) in the urine and reduced liver and spleen volumes. Most importantly, these two patients are experiencing early signs of stabilized or improved neurocognitive measures." (2/17/2017)
  • Cantor Fitzgerald analysts commented, "We are reiterating our Overweight rating and $21 price target on shares of ABEO this morning, following initial cognitive and behavioral assessment data presented at the 13th Annual WORLDSymposium' meeting in San Diego, California. We believe data from the Phase 1/2 study in patients treated with low-dose ABO-102 demonstrate functional evidence of ABO-102's benefit across several cognitive and behavioral domains. Encouraged by ABO-102's emerging profile, we believe the study's second cohort, treating younger patients at a higher dose, will provide more information on the drug's clinical benefit." (2/17/2017)
  • Jefferies Group LLC analysts commented, "ABO-102 Ph1/2 longer follow-up data in MPS IIIA at WORLDSymposium showed continued reduction in CSF GAG at 6 mon (n=2), while urinary GAG reduction appeared to plateau. Early sign of neurocognitive benefits was shown at 6mon (measured by Leiter-3), which we see as encouraging. We see potentially further improvement with longer follow-up based on KOL feedback." (2/17/2017)
  • According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (2/8/2017)

Who owns Abeona Therapeutics stock?

Abeona Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Soros Fund Management LLC (2.24%), Perceptive Advisors LLC (2.11%), Opaleye Management Inc. (1.00%), Kavi Asset Management LP (0.91%), Royce & Associates LP (0.78%) and Allianz Asset Management AG (0.12%). Company insiders that own Abeona Therapeutics stock include Mark J Ahn and Todd Wider.

Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?

Abeona Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Soros Fund Management LLC and Royce & Associates LP.

Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?

Abeona Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Kavi Asset Management LP, Opaleye Management Inc., Allianz Asset Management AG, GLG Partners LP, Tudor Investment Corp Et Al and A.R.T. Advisors LLC. Company insiders that have bought Abeona Therapeutics stock in the last two years include Mark J Ahn and Todd Wider.

How do I buy Abeona Therapeutics stock?

Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abeona Therapeutics stock cost?

One share of Abeona Therapeutics stock can currently be purchased for approximately $5.10.

Abeona Therapeutics (NASDAQ:ABEO) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Earnings History Chart

Earnings by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Dividend History Chart

Dividend Payments by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Last Updated on 2/23/2017 by MarketBeat.com Staff